MINI FUTURE SHORT - ELI LILLY & CO | Market Closed - Bid/Ask 16:20:00 30/05/2024 BST | After market 16:15:00 | |||
| 0.46 CHF | -9.80% |
|
0.465 | +1.09% |
| Current month | -62.30% | ||
| 1 month | -62.30% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 30/05/24 | 0.46 | -9.80% |
| 29/05/24 | 0.51 | -8.93% |
| 28/05/24 | 0.56 | +9.80% |
| 27/05/24 | 0.51 | -1.92% |
| 24/05/24 | 0.52 | +4.00% |
Delayed Quote Swiss Exchange
Last update May 30, 2024 at 04:20 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| VXSABP | |
| ISIN | CH1332894398 |
| Date issued | 22/03/2024 |
| Strike | 866 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | - CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 1.31 CHF |
|---|---|
| Lowest since issue | 0.46 CHF |
| Spread | 0.01 CHF |
| Spread % | 2.13% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
820.3
USD
Average target price
852.5
USD
Spread / Average Target
+3.92%
- Stock Market
- Certificates
- VXSABP Certificat
